Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of Tuesday, October 6, 2026.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
Veraxa Biotech Holding AG
Market Cap
$152.72M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.58M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-138.87%
3Y Avg
-97.17%
5Y Avg
-81.85%
Market Cap
$153.79M
Return on Invested Capital (ROIC)
-22.15%
TTM Avg
-29.24%
3Y Avg
-31.64%
5Y Avg
-30.48%
Market Cap
$151.01M
Return on Invested Capital (ROIC)
-165.56%
TTM Avg
-176.54%
3Y Avg
-127.81%
5Y Avg
-112.12%
Market Cap
$149.36M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$156.22M
Return on Invested Capital (ROIC)
-13.94%
TTM Avg
-16.11%
3Y Avg
-25.11%
5Y Avg
-17.04%
Market Cap
$148.73M
Return on Invested Capital (ROIC)
-134.15%
TTM Avg
-47.87%
3Y Avg
-96.96%
5Y Avg
-96.99%
Market Cap
$148.64M
Return on Invested Capital (ROIC)
-64.72%
TTM Avg
-41.34%
3Y Avg
-24.79%
5Y Avg
-23.17%
Market Cap
$148.27M
Return on Invested Capital (ROIC)
-27.25%
TTM Avg
-49.08%
3Y Avg
-43.31%
5Y Avg
-52.54%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | -138.87% | -97.17% | -81.85% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -22.15% | -29.24% | -31.64% | -30.48% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -165.56% | -176.54% | -127.81% | -112.12% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -56.53% | -185.89% | -125.01% | -88.85% |
| Inogen, Inc. (INGN)vs › | $156.22M | -13.94% | -16.11% | -25.11% | -17.04% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -134.15% | -47.87% | -96.96% | -96.99% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -64.72% | -41.34% | -24.79% | -23.17% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -27.25% | -49.08% | -43.31% | -52.54% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -118.67% | -87.91% | -55.09% | -41.64% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
